EN DE
Watch BioLineRx Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BioLineRx Ltd (BLRX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of BioLineRx Ltd stock $1.56, price $1.52, upside +2.6%, quality 36 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Israel

BL BioLineRx Ltd logo Thin data Nov 10, 2026

BioLineRx Ltd

BLRX · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Fair value $1.56 · Fairly valued
Mixed vs. peers (5/10)
Quality 36/100
Weak Growth (revenue YoY −95.9 %/yr in USD)
Loss-making · -99.6% net margin (FY2025)
Negative free cash flow
Narrow moat 5/100
Thin data
Estimate
Watch BioLineRx Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$122.40 $1.52 Fair Value $1.56 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $1.52 – $122.40 · fair‑value band $1.17 – $1.95 · the $1.52 price screens below the $1.56 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow BioLineRx in your weekly email

Every Wednesday you see whether BioLineRx is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.

Show moreShow less

The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Stock analysis

BioLineRx Ltd (BLRX) currently trades at $1.52, while our estimate is $1.56, so the stock looks roughly fairly valued today (gap 2.6%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.17 (bear) to $1.95 (bull), the price of $1.52 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

BioLineRx Ltd reported revenue of $1.2M in FY2025 versus $0 in FY2021. Reported net income was −$1.2M in FY2025.

Key figures

Market cap $7.7M Micro · P/S ratio 7.22 · Net margin −99.6% · Return on equity −55.3% · Return on assets (EBIT) −44.8% (5-year average) · Operating margin −1,215% · Revenue (TTM) $1.4M · Revenue growth (YoY) −3.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 60% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 3%, BLRX screens cheaper than that median.

Fair Value

Bear $1.17 Fair Value $1.56 Bull $1.95
Price $1.52 · Upside +2.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 41
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 42
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−95.9%
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−99.0% (2009) → −871.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch BLRX, get fair value alerts →

Compare BioLineRx Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside +2.6% · Top 25%
Profitability
Return on assets −2.9% · Above median
Net margin (12 months) −99.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −3.3% · Below median
Balance sheet
Debt / equity 0.25× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.42× · Cheapest 25%
P/S (12 months) 5.52× · Cheaper than median
PEG 0.20× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)37 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)88 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs BLRX
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs BLRX
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs BLRX
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs BLRX
argenx SE ARGX $971.55 $908.40 −7% vs BLRX
CSL Limited CSL A$201.68 A$181.40 −10% vs BLRX
Moderna, Inc MRNA $250.83 $158.70 −37% vs BLRX
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs BLRX
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs BLRX
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs BLRX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BioLineRx Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BioLineRx Ltd Fair Value". https://www.fairvalue-calculator.com/stock/BLRX

Frequently asked questions

Is BioLineRx Ltd (BLRX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $1.56 versus a price of $1.52, about +3% upside (fairly valued).
What is the fair value of BLRX?
Our estimate for BioLineRx Ltd is $1.56 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.52.
What is the quality score of BLRX?
BioLineRx Ltd has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioLineRx Ltd (BLRX)?
Our calculated price target is the estimate of $1.56 (as of Nov 10, 2026). Cautious scenario $1.17, optimistic scenario $1.95. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the BioLineRx Ltd stock forecast for 2026?
Our estimate puts fair value at $1.56, about +3% upside versus a price of $1.52 (fairly valued). Cautious scenario $1.17, optimistic scenario $1.95. The calculation is refreshed regularly with new filings.
What is the revenue of BioLineRx Ltd (BLRX)?
BioLineRx Ltd reported trailing-twelve-month revenue of about $1.4M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of BioLineRx Ltd (BLRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioLineRx Ltd it is $1.56 per share (as of Nov 10, 2026), against a price of $1.52.
Is BioLineRx Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, BLRX trades below its calculated fair value: price $1.52, fair value $1.56, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BLRX?
No. The price is what the market pays today ($1.52); the fair value is what the company's own numbers justify ($1.56). For BioLineRx Ltd the two are $0.0400 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioLineRx Ltd worth?
The market values BioLineRx Ltd at about $7.7M (market capitalisation, as of Nov 10, 2026). Per share that is $1.52; our models calculate a fair value of $1.56 per share.
What do the bullish and bearish scenarios say about BLRX?
Our models span a range for BioLineRx Ltd: cautious scenario $1.17, base $1.56, optimistic $1.95 per share (as of Nov 10, 2026, price $1.52). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of BLRX?
The PEG ratio of BioLineRx Ltd is 0.20 (P/E divided by earnings growth, as of Nov 10, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of BioLineRx Ltd (BLRX)?
Balance-sheet figures for BioLineRx Ltd (as of Nov 10, 2026): return on equity −55.3%, debt of 0.25 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is BLRX from its 52-week high?
BioLineRx Ltd trades at $1.52, about 60% below its 52-week high of $3.78 and at the low of $1.52 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $1.56 is for.
Which stocks are comparable to BioLineRx Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioLineRx Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price $1.52, calculated fair value $1.56 (+3%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. BioLineRx Ltd currently trades 3% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioLineRx Ltd (BLRX)?
The closing price on Nov 10, 2026 was $1.52. Our estimate is $1.56, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioLineRx Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of BioLineRx Ltd

How large is the market capitalisation of BioLineRx Ltd (BLRX)?
The market capitalisation of BioLineRx Ltd is $7.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioLineRx Ltd (BLRX)?
The price-to-sales ratio of BioLineRx Ltd is 7.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of BioLineRx Ltd (BLRX)?
The net margin of BioLineRx Ltd is −99.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioLineRx Ltd (BLRX)?
The return on equity (ROE) of BioLineRx Ltd is −55.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioLineRx Ltd (BLRX)?
On an EBIT basis the return on assets of BioLineRx Ltd is −44.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioLineRx Ltd (BLRX)?
The operating margin of BioLineRx Ltd is −1,215% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioLineRx Ltd (BLRX)?
Revenue at BioLineRx Ltd is growing −3.3% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BioLineRx Ltd (BLRX) generate?
The free cash flow of BioLineRx Ltd is −$8.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does BioLineRx Ltd (BLRX) carry?
The net debt of BioLineRx Ltd is $6.9M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch BioLineRx Ltd in the live analysis

One click puts BioLineRx Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.